BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 11757244)

  • 1. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
    Hofstra RM; van der Luijt RB; Lips CJ
    Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [One gene--four diseases: on the importance of mutations in the ret gene in MEN 2A, MEN 2B, Hirschsprung disease and medullary thyroid carcinoma].
    Fehmann HC; Göke B
    Z Gastroenterol; 1994 Jul; 32(7):416-7. PubMed ID: 7975780
    [No Abstract]   [Full Text] [Related]  

  • 3. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
    Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
    Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2.
    Mulligan LM; Ponder BA
    J Clin Endocrinol Metab; 1995 Jul; 80(7):1989-95. PubMed ID: 7608246
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
    Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
    J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
    Eng C; Mulligan LM
    Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
    Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
    Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan.
    Iihara M; Yamashita T; Okamoto T; Kanbe M; Yamazaki K; Egawa S; Yamaguchi K; Obara T
    Jpn J Clin Oncol; 1997 Jun; 27(3):128-34. PubMed ID: 9255265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putting the bits and pieces of the RET proto-oncogene puzzle together.
    Gagel RF
    Bone; 1995 Aug; 17(2 Suppl):13S-16S. PubMed ID: 8579892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The physical map of the human RET proto-oncogene.
    Pasini B; Hofstra RM; Yin L; Bocciardi R; Santamaria G; Grootscholten PM; Ceccherini I; Patrone G; Priolo M; Buys CH
    Oncogene; 1995 Nov; 11(9):1737-43. PubMed ID: 7478601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET mutations in multiple endocrine neoplasia type 2 and Hirschsprung disease.
    Reynolds LF; Eng C
    Curr Opin Pediatr; 1995 Dec; 7(6):702-9. PubMed ID: 8776023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
    Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y
    J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET gene and its implications for cancer.
    Goodfellow PJ; Wells SA
    J Natl Cancer Inst; 1995 Oct; 87(20):1515-23. PubMed ID: 7563185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.